Phase III eXalt3 study shows ensartinib is far superior to crizotinib in ALK+ NSCLC

Written by Louis Gautier, Future Science Group

Recent interim results from the ongoing Phase III eXalt3 trial have shown that NSCLC patients with anaplastic lymphoma kinase (ALK) gene alterations experience a substantially longer progression-free survival (PFS) when treated with ensartinib over crizotinib (Xalkori ®). Presented at the International Association for the Study of Lung Cancer World Conference, the results show that NSCLC patients treated with ensartinib, a novel next-generation ALK tyrosine kinase inhibitor (TKI), resulted in a 2-fold increase in PFS when compared with crizotinib-treated patients. The results come from a planned interim analysis of the eXalt3 study following 75% of PFS events. The overall response rate...

To view this content, please register now for access

It's completely free